Health TrialsbyHealthPanel

Comorbidity Between Attention Deficit Hyperactivity Disorder and Fibromyalgia

ConditionsADHD - Attention Deficit Disorder With HyperactivityFibromyalgia (FM)Chronic Pain
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-100
SponsorUniversity Hospital, Tours

About this trial

The overall objective of the research project presented here is to assess the prevalence of fibromyalgia in patients being treated for ADHD, the prevalence of ADHD in patients being treated for fibromyalgia, and the neurobiological correlates of ADHD-fibromyalgia comorbidity.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Men or women aged 18 or over

Diagnosis of fibromyalgia

Affiliated with a social security scheme

Having signed an informed consent form

Disqualifiers

For patients with fibromyalgia: existence of another condition explaining chronic pain

Severe cognitive impairment

Difficulties in understanding self-administered questionnaires

Difficulties in assessing pain intensity

Trial design

Design model

Single group

Treatments tested in this trial

  • Samples

    Biological/Vaccine

    Blood and urine samples including metabolomic analyses.

  • Questionnaires

    Other intervention

    Completing self-assessment questionnaires

  • Sensitivity to mechanical pain

    Other intervention

    Assessment of sensitivity to mechanical pain (by using the Von Frey monofilament test)

Treatment groups

100 Participants
are divided into 1 treatment group
Group A: Patients with fibromyalgia being treated for ADHDExperimental treatment 3 interventions

Trial outcomes

Primary outcomes

1

Percentage of patients with fibromyalgia among patients with ADHD and no prior methylphenidate treatment

Comparison of the observed prevalence of fibromyalgia (as assessed by the ACR diagnostic criteria) among patients with ADHD (as assessed by the DIVA-5 diagnostic interview) and no prior methylphenidate treatment versus the theoretical prevalence of fibromyalgia in the overall French population

Time frame
Baseline

Secondary outcomes

1

Percentage of patients with fibromyalgia among patients with ADHD and a current methylphenidate treatment

Comparison of the observed prevalence of fibromyalgia (as assessed by the ACR diagnostic criteria) among patients with ADHD (as assessed by the DIVA-5 diagnostic interview) and a current methylphenidate treatment versus the theoretical prevalence of fibromyalgia in the French overall population

Time frame
Baseline
2

Comparison of the levels of cytokines (specific biomarkers of inflammation), between patients with fibromyalgia without ADHD

Plasma and urine levels of different cytokines (IFN-gamma, IL-1B, IL-6, IL10, IL-13, IL-17, TNF-alpha), as assessed by metabolomic analyses (high-performance liquid chromatography)

Time frame
Baseline
3

Comparison of the levels of cytokines (specific biomarkers of inflammation), between patients with ADHD without fibromyalgia

Plasma and urine levels of different cytokines (IFN-gamma, IL-1B, IL-6, IL10, IL-13, IL-17, TNF-alpha), as assessed by metabolomic analyses (high-performance liquid chromatography)

Time frame
Baseline
4

Comparison of the levels of cytokines (specific biomarkers of inflammation), between patients with fibromyalgia with ADHD

Plasma and urine levels of different cytokines (IFN-gamma, IL-1B, IL-6, IL10, IL-13, IL-17, TNF-alpha), as assessed by metabolomic analyses (high-performance liquid chromatography)

Time frame
Baseline

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University Hospital, Tours

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: